Aspen Neuroscience, Inc. (ASPE) Stock Price & Analysis
Aspen Neuroscience, Inc. (ASPE) closed at USD 12.29 on Tuesday, November 3, 2026, down 5.75% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 13.04; the Nov 3, 2026 session ranged USD 12–14.49 on volume of 639,069 shares. Market capitalization is $357.38M, with a 52-week range of USD 11.6–14.9 (NMS). Source: Nexqual, retrieved November 4, 2026 at 03:26 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ASPE.md
Key facts (ASPE)
- Insider open-market purchases, last ~7 months: 2 Form 4 filings, $38.0M; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: None.
- Total return with dividends: 1Y -17.5% vs S&P 500 +12.9%; 5Y -17.5% vs S&P 500 +72.1%.
- Dividend: ASPE paid no cash dividend in the last five years.
Insider purchases (SEC Form 4, open-market, last ~7 months) (ASPE)
2 purchases, $38.0M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-11-02 | Arch Venture Fund X, L.P. | 1,333,333 | $20.0M | 15 | Too little history (no open-market trades in 2023–2025) | |
| 2026-11-02 | Arch Venture Partners Xiv, L.P. | 1,200,000 | $18.0M | 15 | Too little history (no open-market trades in 2023–2025) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (ASPE)
Consensus None.
Total return (dividends reinvested) (ASPE)
| 1Y (from 2026-10-30) | 5Y (from 2026-10-26) | |
|---|---|---|
| Total return | -17.5% | -17.5% |
| S&P 500 (SPY) | +12.9% | +72.1% |
| Per year | — | — |
| Volatility (annualized) | 82.4% | 97.8% |
| Max drawdown | -17.5% (Oct 2026→Nov 2026) | -17.5% (Oct 2026→Nov 2026) |
Dividends (ASPE)
ASPE paid no cash dividend in the last five years.
ASPE recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Nov 3, 2026 | Schedule 13G | Qatar Investment Authority: 6.7% of shares, passive 5%+ holder |
| Nov 2, 2026 | 8-K | Bylaws or fiscal-year change; Other material event “On November 2, 2026, the Company completed the IPO of 9,375,000 shares of the Company's common stock, par value $0.0001 per share, at a price to the public of $15.00 per share. The gross proceeds to the Company from the IPO were approximately $140.6 million, before deducting underwriting discounts and commissions and offering expenses payable by the Company.” |
| Oct 26, 2026 | S-1/A | Registration of new shares |
| Oct 22, 2026 | S-1/A | Registration of new shares |
| Oct 9, 2026 | S-1 | Registration of new shares |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
ASPE analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |
Key Statistics (as of November 4, 2026 at 03:26 UTC)
| Price | USD 12.29 |
|---|---|
| Change | ▼ 5.75% (down) |
| Previous Close | USD 13.04 |
| Open | USD 13 |
| Day Range | USD 12 – 14.49 |
| 52-Week Range | USD 11.6 – 14.9 |
| Volume | 639,069 shares |
| Market Cap | $357.38M |
| Exchange | NMS |
Analyst Ratings (ASPE)
Wall Street analysts rate ASPE "None", per Nexqual as of November 4, 2026 at 03:26 UTC.
| Consensus Rating | None |
|---|
Earnings (ASPE)
Source: Nexqual, November 4, 2026 at 03:26 UTC.
Financials & Fundamentals (ASPE)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Debt / Equity | 0.11 |
| Current Ratio | 4.56 |
| Total Cash | $72.38M |
| Total Debt | $9.77M |
Source: Nexqual, November 4, 2026 at 03:26 UTC.
Financial Health Score (ASPE)
Nexqual rates Aspen Neuroscience, Inc.'s overall financial health "Mixed" across five dimensions, as of November 4, 2026 at 03:26 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% (last 12 months) |
| Balance Sheet | Strong — $72M cash vs $10M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$57M (TTM) |
| Efficiency | Mixed — No data |
Ownership (ASPE)
| Shares Outstanding | 29.08M |
|---|---|
| Float | 20.28M |
Source: Nexqual, November 4, 2026 at 03:26 UTC.
Leadership (ASPE)
Aspen Neuroscience, Inc. is led by Damien McDevitt, President, CEO & Director, per Nexqual as of November 4, 2026 at 03:26 UTC.
| President, CEO & Director | Damien McDevitt |
|---|---|
| Executive Chairman | Faheem Hasnain |
| Chief Financial Officer | Dalen Meeter C.P.A. |
| Chief Technology Officer | Kim Raineri |
| Chief Scientific Officer | Xiaokui Zhang |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KOD | Kodiak Sciences Inc | USD 98.89 | ▲ 1.29% |
| LGND | Ligand Pharmaceuticals Incorpor | USD 313.52 | ▲ 2.12% |
| ORKA | Oruka Therapeutics, Inc. | USD 99.55 | ▲ 4.32% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 40.42 | ▼ 1.99% |
| AXSM | Axsome Therapeutics, Inc. | USD 139.61 | ▲ 2.65% |
| ABVX | Abivax SA | USD 88.71 | ▲ 4.48% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: November 4, 2026 at 03:26 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt